Arrowhead stock climbs as Morgan Stanley upgrades to Overweight, raises target to $100
Arrowhead Pharmaceuticals (ARWR) is rising after Morgan Stanley upgraded the stock to Overweight and lifted its price target to $100 from $78. The call points to a stronger outlook for Arrowhead’s plozasiran severe hypertriglyceridemia Phase 3 program with key results expected in Q3 2026.
1) What’s moving the stock
Arrowhead Pharmaceuticals shares are trading higher in the latest session, tracking renewed buy-side interest after a fresh bullish analyst action. Morgan Stanley upgraded ARWR to Overweight from Equal-Weight and increased its price target to $100 from $78, re-centering attention on Arrowhead’s cardiometabolic pipeline and the upcoming Phase 3 trajectory for plozasiran.
2) The catalyst: plozasiran and the Q3 2026 setup
The upgrade highlights plozasiran, Arrowhead’s investigational RNAi therapy being developed for severe hypertriglyceridemia, as the primary value driver. With pivotal program milestones approaching in 2026, the report frames the next Phase 3 readout window (expected in Q3 2026) as a potential re-rating event if efficacy and safety are consistent with prior results.
3) Why it matters now
Arrowhead has been transitioning from a development-stage RNAi company toward a commercial footing, making late-stage execution and the near-term clinical calendar more important to how investors underwrite the story. An upgrade from a major bank, paired with a higher target, can also trigger incremental flows from investors who screen for rating changes and rising consensus targets.